News
-
-
-
PRESS RELEASE
Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Menarini Group presents new data from Phase 1b/2 ELEVATE Study of Elacestrant in combination with Capivasertib for ER+, HER2- Metastatic Breast Cancer at ASCO Annual Meeting 2026 -
-
-
-
-
-
-